Tacrolimus
Description
Name: Tacrolimus
Type: small molecule
Groups: Array
Indication: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Accession Number: DB00864 ( APRD00276, EXPT01437)
Description: Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
Structure:
Prescription Products:
Generic Prescription Products:
Over the Counter Products: Not Available
Prescription Products:
Generic Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: Array
Indication: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Accession Number: DB00864 ( APRD00276, EXPT01437)
Description: Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condition vitiligo. It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Advagraf | capsule (extended release) | 0.5 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 1 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 5 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 3 mg | oral | 05-04-2010 | Canada | |
| Astagraf XL | capsule, coated, extended release | .5 mg/1 | oral | 19-07-2013 | US | |
| Astagraf XL | capsule, coated, extended release | 1 mg/1 | oral | 19-07-2013 | US | |
| Astagraf XL | capsule, coated, extended release | 5 mg/1 | oral | 19-07-2013 | US | |
| Envarsus XR | tablet, extended release | 1 mg/1 | oral | 01-09-2015 | US | |
| Envarsus XR | tablet, extended release | 4 mg/1 | oral | 01-09-2015 | US | |
| Envarsus XR | tablet, extended release | .75 mg/1 | oral | 01-09-2015 | US | |
| Prograf | capsule | 5 mg | oral | 14-08-1996 | Canada | |
| Prograf | capsule | 1 mg | oral | 14-08-1996 | Canada | |
| Prograf | solution | 5 mg | intravenous | 14-08-1996 | Canada | |
| Prograf | capsule | 0.5 mg | oral | 02-04-2001 | Canada | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | .5 mg/1 | oral | 24-08-1998 | US | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | 5 mg/1 | oral | 08-04-1994 | US | |
| Prograf | injection, solution | 5 mg/mL | intravenous | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Protopic | ointment | .3 mg/g | topical | 08-12-2000 | US | |
| Protopic | ointment | 1 mg/g | topical | 08-12-2000 | US | |
| Protopic | ointment | 1 mg/g | topical | 08-05-2008 | US | |
| Protopic | ointment | 0.1 % | topical | 06-09-2001 | Canada | |
| Protopic | ointment | 0.03 % | topical | 06-09-2001 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 0.5 mg | oral | 11-06-2014 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 1 mg | oral | 25-11-2013 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 5 mg | oral | 25-11-2013 | Canada | |
| Tacrolimus | ointment | .3 mg/g | topical | 20-11-2014 | US | |
| Tacrolimus | ointment | 1 mg/g | topical | 20-11-2014 | US |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Hecoria | capsule | .5 mg/1 | oral | 20-12-2011 | US | |
| Hecoria | capsule | 1 mg/1 | oral | 20-12-2011 | US | |
| Hecoria | capsule | 5 mg/1 | oral | 20-12-2011 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 15-06-2011 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-06-2011 | US | |
| Tacrolimus | ointment | 1 mg/g | topical | 09-09-2014 | US | |
| Tacrolimus | ointment | .3 mg/g | topical | 09-09-2014 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-12-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 01-11-2010 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-11-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 01-11-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 05-01-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 1 mg/1 | oral | 30-10-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 06-07-2010 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule, gelatin coated | .5 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 1 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 5 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 10-08-2009 | US |
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Advagraf | capsule (extended release) | 0.5 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 1 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 5 mg | oral | 09-04-2008 | Canada | |
| Advagraf | capsule (extended release) | 3 mg | oral | 05-04-2010 | Canada | |
| Astagraf XL | capsule, coated, extended release | .5 mg/1 | oral | 19-07-2013 | US | |
| Astagraf XL | capsule, coated, extended release | 1 mg/1 | oral | 19-07-2013 | US | |
| Astagraf XL | capsule, coated, extended release | 5 mg/1 | oral | 19-07-2013 | US | |
| Envarsus XR | tablet, extended release | 1 mg/1 | oral | 01-09-2015 | US | |
| Envarsus XR | tablet, extended release | 4 mg/1 | oral | 01-09-2015 | US | |
| Envarsus XR | tablet, extended release | .75 mg/1 | oral | 01-09-2015 | US | |
| Prograf | capsule | 5 mg | oral | 14-08-1996 | Canada | |
| Prograf | capsule | 1 mg | oral | 14-08-1996 | Canada | |
| Prograf | solution | 5 mg | intravenous | 14-08-1996 | Canada | |
| Prograf | capsule | 0.5 mg | oral | 02-04-2001 | Canada | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | .5 mg/1 | oral | 24-08-1998 | US | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | 5 mg/1 | oral | 08-04-1994 | US | |
| Prograf | injection, solution | 5 mg/mL | intravenous | 08-04-1994 | US | |
| Prograf | capsule, gelatin coated | 1 mg/1 | oral | 08-04-1994 | US | |
| Protopic | ointment | .3 mg/g | topical | 08-12-2000 | US | |
| Protopic | ointment | 1 mg/g | topical | 08-12-2000 | US | |
| Protopic | ointment | 1 mg/g | topical | 08-05-2008 | US | |
| Protopic | ointment | 0.1 % | topical | 06-09-2001 | Canada | |
| Protopic | ointment | 0.03 % | topical | 06-09-2001 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 0.5 mg | oral | 11-06-2014 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 1 mg | oral | 25-11-2013 | Canada | |
| Sandoz Tacrolimus | capsule (immediate release) | 5 mg | oral | 25-11-2013 | Canada | |
| Tacrolimus | ointment | .3 mg/g | topical | 20-11-2014 | US | |
| Tacrolimus | ointment | 1 mg/g | topical | 20-11-2014 | US |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Hecoria | capsule | .5 mg/1 | oral | 20-12-2011 | US | |
| Hecoria | capsule | 1 mg/1 | oral | 20-12-2011 | US | |
| Hecoria | capsule | 5 mg/1 | oral | 20-12-2011 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 15-06-2011 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-06-2011 | US | |
| Tacrolimus | ointment | 1 mg/g | topical | 09-09-2014 | US | |
| Tacrolimus | ointment | .3 mg/g | topical | 09-09-2014 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-12-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 10-08-2009 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 01-11-2010 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-11-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 01-11-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 28-09-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 05-01-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 1 mg/1 | oral | 30-10-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 14-05-2010 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 06-07-2010 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 31-08-2011 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 23-07-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 17-07-2013 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 15-01-2012 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule | 1 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule | 5 mg/1 | oral | 13-08-2014 | US | |
| Tacrolimus | capsule, gelatin coated | .5 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 1 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule, gelatin coated | 5 mg/1 | oral | 30-07-2015 | US | |
| Tacrolimus | capsule | .5 mg/1 | oral | 10-08-2009 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Hecoria | Tacrolimus |
| Hecoria | Tacrolimus |
| Hecoria | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Prograf | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Prograf | Tacrolimus |
| Protopic | Tacrolimus |
| Protopic | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Protopic | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Protopic | Tacrolimus |
| Protopic | Tacrolimus |
| Brand Name | Ingredients |
|---|---|
| Hecoria | Tacrolimus |
| Hecoria | Tacrolimus |
| Hecoria | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Prograf | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Astagraf XL | Tacrolimus |
| Prograf | Tacrolimus |
| Protopic | Tacrolimus |
| Protopic | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Protopic | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Prograf | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Tacrolimus | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Envarsus XR | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Prograf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Advagraf | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Sandoz Tacrolimus | Tacrolimus |
| Protopic | Tacrolimus |
| Protopic | Tacrolimus |
Categories
- No Category
Pharmacology
Indication: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
Pharmacodynamics: Not Available
Mechanism of action: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.
Absorption: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17±10%; in adults liver transplant patients is 22±6%; in healthy subjects is 18±5%. The absolute bioavailability in pediatric liver transplant patients was 31±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.
Volume of distribution:
Protein binding: ~99% bound to human plasma protein, primarily to albumin and alpha-1-acid glycoprotein. This is independent of concentration over a range of 5-50 ng/mL.
Metabolism: Not Available
Route of elimination: In man, less than 1% of the dose administered is excreted unchanged in urine. When administered IV, fecal elimination accounted for 92.6±30.7%, urinary elimination accounted for 2.3±1.1%.
Half life: The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.
Clearance: Not Available
Toxicity: Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD50=134-194 mg/kg (rat).
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.
Absorption: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17±10%; in adults liver transplant patients is 22±6%; in healthy subjects is 18±5%. The absolute bioavailability in pediatric liver transplant patients was 31±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition.
Volume of distribution:
- 2.6 ± 2.1 L/kg [pediatric liver transplant patients]
- 1.07 ± 0.20 L/kg [patients with renal impairment, 0.02 mg/kg/4 hr dose, IV]
- 3.1 ± 1.6 L/kg [Mild Hepatic Impairment, 0.02 mg/kg/4 hr dose, IV]
- 3.7 ± 4.7 L/kg [Mild Hepatic Impairment, 7.7 mg dose, PO]
- 3.9 ± 1.0 L/kg [Severe hepatic impairment, 0.02 mg/kg/4 hr dose, IV]
- 3.1 ± 3.4 L/kg [Severe hepatic impairment, 8 mg dose, PO]
Protein binding: ~99% bound to human plasma protein, primarily to albumin and alpha-1-acid glycoprotein. This is independent of concentration over a range of 5-50 ng/mL.
Metabolism: Not Available
Route of elimination: In man, less than 1% of the dose administered is excreted unchanged in urine. When administered IV, fecal elimination accounted for 92.6±30.7%, urinary elimination accounted for 2.3±1.1%.
Half life: The elimination half life in adult healthy volunteers, kidney transplant patients, liver transplants patients, and heart transplant patients are approximately 35, 19, 12, 24 hours, respectively. The elimination half life in pediatric liver transplant patients was 11.5±3.8 hours, in pediatric kidney transplant patients was 10.2±5.0 (range 3.4-25) hours.
Clearance: Not Available
Toxicity: Side effects can be severe and include blurred vision, liver and kidney problems (it is nephrotoxic), seizures, tremors, hypertension, hypomagnesemia, diabetes mellitus, hyperkalemia, itching, insomnia, confusion. LD50=134-194 mg/kg (rat).
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Astellas pharma us inc
- Dr reddys laboratories ltd
- Sandoz inc
- Watson laboratories inc
- Astellas Pharma US
Packagers:
- Astellas Pharma Inc.
- B&B Pharmaceuticals
- Cardinal Health
- Caremark LLC
- Doctor Reddys Laboratories Ltd.
- Kaiser Foundation Hospital
- Mckesson Corp.
- Murfreesboro Pharmaceutical Nursing Supply
- Neuman Distributors Inc.
- Physicians Total Care Inc.
- Rebel Distributors Corp.
- Sandoz
- Watson Pharmaceuticals
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Capsule (extended release) | oral | 0.5 mg |
| Capsule (extended release) | oral | 1 mg |
| Capsule (extended release) | oral | 3 mg |
| Capsule (extended release) | oral | 5 mg |
| Capsule, coated, extended release | oral | .5 mg/1 |
| Capsule, coated, extended release | oral | 1 mg/1 |
| Capsule, coated, extended release | oral | 5 mg/1 |
| Tablet, extended release | oral | .75 mg/1 |
| Tablet, extended release | oral | 1 mg/1 |
| Tablet, extended release | oral | 4 mg/1 |
| Capsule | oral | .5 mg/1 |
| Capsule | oral | 1 mg/1 |
| Capsule | oral | 5 mg/1 |
| Capsule | oral | 0.5 mg |
| Capsule | oral | 1 mg |
| Capsule | oral | 5 mg |
| Capsule, gelatin coated | oral | .5 mg/1 |
| Capsule, gelatin coated | oral | 1 mg/1 |
| Capsule, gelatin coated | oral | 5 mg/1 |
| Injection, solution | intravenous | 5 mg/mL |
| Solution | intravenous | 5 mg |
| Ointment | topical | 0.03 % |
| Ointment | topical | 0.1 % |
| Capsule (immediate release) | oral | 0.5 mg |
| Capsule (immediate release) | oral | 1 mg |
| Capsule (immediate release) | oral | 5 mg |
| Ointment | topical | .3 mg/g |
| Ointment | topical | 1 mg/g |
| Form | Route | Strength |
|---|---|---|
| Capsule (extended release) | oral | 0.5 mg |
| Capsule (extended release) | oral | 1 mg |
| Capsule (extended release) | oral | 3 mg |
| Capsule (extended release) | oral | 5 mg |
| Capsule, coated, extended release | oral | .5 mg/1 |
| Capsule, coated, extended release | oral | 1 mg/1 |
| Capsule, coated, extended release | oral | 5 mg/1 |
| Tablet, extended release | oral | .75 mg/1 |
| Tablet, extended release | oral | 1 mg/1 |
| Tablet, extended release | oral | 4 mg/1 |
| Capsule | oral | .5 mg/1 |
| Capsule | oral | 1 mg/1 |
| Capsule | oral | 5 mg/1 |
| Capsule | oral | 0.5 mg |
| Capsule | oral | 1 mg |
| Capsule | oral | 5 mg |
| Capsule, gelatin coated | oral | .5 mg/1 |
| Capsule, gelatin coated | oral | 1 mg/1 |
| Capsule, gelatin coated | oral | 5 mg/1 |
| Injection, solution | intravenous | 5 mg/mL |
| Solution | intravenous | 5 mg |
| Ointment | topical | 0.03 % |
| Ointment | topical | 0.1 % |
| Capsule (immediate release) | oral | 0.5 mg |
| Capsule (immediate release) | oral | 1 mg |
| Capsule (immediate release) | oral | 5 mg |
| Ointment | topical | .3 mg/g |
| Ointment | topical | 1 mg/g |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Tacrolimus anhydrous 0.5 mg cap | $2.23 | each |
| Prograf 0.5 mg capsule | $2.43 | capsule |
| Protopic 0.03% ointment | $4.09 | g |
| Protopic 0.1% ointment | $4.17 | g |
| Tacrolimus anhydrous 1 mg cap | $4.46 | each |
| Tacrolimus 1 mg capsule | $4.64 | capsule |
| Prograf 1 mg capsule | $4.85 | capsule |
| Tacrolimus anhydrous 5 mg cap | $22.3 | each |
| Prograf 5 mg capsule | $24.26 | capsule |
| Protopic 0.1% Ointment 30 gm Tube | $124.42 | tube |
| Protopic 0.03% Ointment 30 gm Tube | $132.99 | tube |
| Prograf 5 mg/ml ampule | $163.94 | ml |
| Protopic 0.03% Ointment 60 gm Tube | $251.17 | tube |
| Protopic 0.1% Ointment 60 gm Tube | $255.34 | tube |
| Tacrolimus micronized powder | $2800.0 | g |
| Unit description | Cost | Unit |
|---|---|---|
| Tacrolimus anhydrous 0.5 mg cap | $2.23 | each |
| Prograf 0.5 mg capsule | $2.43 | capsule |
| Protopic 0.03% ointment | $4.09 | g |
| Protopic 0.1% ointment | $4.17 | g |
| Tacrolimus anhydrous 1 mg cap | $4.46 | each |
| Tacrolimus 1 mg capsule | $4.64 | capsule |
| Prograf 1 mg capsule | $4.85 | capsule |
| Tacrolimus anhydrous 5 mg cap | $22.3 | each |
| Prograf 5 mg capsule | $24.26 | capsule |
| Protopic 0.1% Ointment 30 gm Tube | $124.42 | tube |
| Protopic 0.03% Ointment 30 gm Tube | $132.99 | tube |
| Prograf 5 mg/ml ampule | $163.94 | ml |
| Protopic 0.03% Ointment 60 gm Tube | $251.17 | tube |
| Protopic 0.1% Ointment 60 gm Tube | $255.34 | tube |
| Tacrolimus micronized powder | $2800.0 | g |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 1338491 | Canada | 1996-07-30 | 2013-07-30 |
| 2037408 | Canada | 2002-12-17 | 2011-03-01 |
| 5260301 | United States | 1994-02-28 | 2011-02-28 |
| 5665727 | United States | 1994-09-09 | 2014-09-09 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Abatacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Abatacept. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus. |
| Adalimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab. |
| ado-trastuzumab emtansine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with ado-trastuzumab emtansine. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Tacrolimus. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alemtuzumab. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus. |
| Altretamine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Altretamine. |
| Amiloride | Amiloride may increase the hyperkalemic activities of Tacrolimus. |
| Amlodipine | The serum concentration of Tacrolimus can be increased when it is combined with Amlodipine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Amsacrine. |
| Anakinra | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra. |
| Anti-thymocyte Globulin (Rabbit) | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anti-thymocyte Globulin (Rabbit). |
| Aprepitant | The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant. |
| Atazanavir | The metabolism of Tacrolimus can be decreased when combined with Atazanavir. |
| Azacitidine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azathioprine. |
| Azithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin. |
| Basil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basil. |
| Basiliximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basiliximab. |
| Batimastat | The metabolism of Tacrolimus can be decreased when combined with Batimastat. |
| Belatacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belimumab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Betamethasone. |
| Bexarotene | The serum concentration of Tacrolimus can be decreased when it is combined with Bexarotene. |
| Bleomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Bleomycin. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Blinatumomab. |
| Boceprevir | The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Tacrolimus can be decreased when it is combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Brentuximab vedotin. |
| Budesonide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide. |
| Busulfan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Busulfan. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus. |
| Canakinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Canakinumab. |
| Capecitabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Capecitabine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carboplatin. |
| Carmustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carmustine. |
| Caspofungin | The serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin. |
| Celecoxib | Celecoxib may increase the nephrotoxic activities of Tacrolimus. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Certolizumab pegol. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Chlorambucil. |
| Chloramphenicol | The serum concentration of Tacrolimus can be increased when it is combined with Chloramphenicol. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus. |
| Choline fenofibrate | Tacrolimus may increase the nephrotoxic activities of Choline fenofibrate. |
| Cinacalcet | The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet. |
| Cisplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cisplatin. |
| Citalopram | Tacrolimus may increase the QTc-prolonging activities of Citalopram. |
| Cladribine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cladribine. |
| Clarithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin. |
| Clofarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clofarabine. |
| Clotrimazole | The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole. |
| Clozapine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clozapine. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Tacrolimus. |
| Conivaptan | The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan. |
| Corticotropin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cortisone acetate. |
| Crizotinib | The serum concentration of Tacrolimus can be increased when it is combined with Crizotinib. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide. |
| Cyclosporine | Tacrolimus may increase the nephrotoxic activities of Cyclosporine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cytarabine. |
| Dabigatran etexilate | The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrolimus. |
| Dabrafenib | The serum concentration of Tacrolimus can be decreased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dactinomycin. |
| Danazol | The serum concentration of Tacrolimus can be increased when it is combined with Danazol. |
| Darunavir | The metabolism of Tacrolimus can be decreased when combined with Darunavir. |
| Dasatinib | The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Daunorubicin. |
| Deferasirox | The serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone. |
| Diclofenac | Diclofenac may increase the nephrotoxic activities of Tacrolimus. |
| Diflunisal | Diflunisal may increase the nephrotoxic activities of Tacrolimus. |
| Diltiazem | The metabolism of Tacrolimus can be decreased when combined with Diltiazem. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dinutuximab. |
| Docetaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel. |
| Dofetilide | Tacrolimus may increase the QTc-prolonging activities of Dofetilide. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxorubicin. |
| Dronedarone | Tacrolimus may increase the QTc-prolonging activities of Dronedarone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Eculizumab. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Tacrolimus. |
| Efavirenz | The serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz. |
| Efonidipine | The serum concentration of Tacrolimus can be increased when it is combined with Efonidipine. |
| Enzalutamide | The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Epirubicin. |
| Eplerenone | Eplerenone may increase the hyperkalemic activities of Tacrolimus. |
| Ertapenem | The serum concentration of Tacrolimus can be increased when it is combined with Ertapenem. |
| Erythromycin | The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin. |
| Esomeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Esomeprazole. |
| Estramustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Estramustine. |
| Etanercept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etanercept. |
| Ethanol | Ethanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Etodolac | Etodolac may increase the nephrotoxic activities of Tacrolimus. |
| Etoposide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etoposide. |
| Everolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Everolimus. |
| Felodipine | The serum concentration of Tacrolimus can be increased when it is combined with Felodipine. |
| Fenofibrate | Tacrolimus may increase the nephrotoxic activities of Fenofibrate. |
| Fenoprofen | Fenoprofen may increase the nephrotoxic activities of Tacrolimus. |
| Fingolimod | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fingolimod. |
| Floctafenine | Floctafenine may increase the nephrotoxic activities of Tacrolimus. |
| Floxuridine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Floxuridine. |
| Fluconazole | The metabolism of Tacrolimus can be decreased when combined with Fluconazole. |
| Fludarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludarabine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluorouracil. |
| Flurbiprofen | Flurbiprofen may increase the nephrotoxic activities of Tacrolimus. |
| Fluticasone Propionate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluticasone Propionate. |
| Fosamprenavir | The metabolism of Tacrolimus can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The serum concentration of Tacrolimus can be increased when it is combined with Fosaprepitant. |
| Foscarnet | Foscarnet may increase the nephrotoxic activities of Tacrolimus. |
| Fosphenytoin | The serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin. |
| Fusidic Acid | The serum concentration of Tacrolimus can be increased when it is combined with Fusidic Acid. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemcitabine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemtuzumab ozogamicin. |
| Glatiramer Acetate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Glatiramer Acetate. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tacrolimus. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Tacrolimus. |
| golimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with golimumab. |
| Goserelin | Tacrolimus may increase the QTc-prolonging activities of Goserelin. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydroxyurea. |
| Ibritumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibritumomab. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibrutinib. |
| Ibuprofen | Ibuprofen may increase the nephrotoxic activities of Tacrolimus. |
| Idarubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Idarubicin. |
| Idelalisib | The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ifosfamide. |
| Imatinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imatinib. |
| Imiquimod | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imiquimod. |
| Indinavir | The metabolism of Tacrolimus can be decreased when combined with Indinavir. |
| Indomethacin | Indomethacin may increase the nephrotoxic activities of Tacrolimus. |
| Infliximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab. |
| Insulin Aspart | The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tacrolimus. |
| Insulin Detemir | The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tacrolimus. |
| Insulin Glargine | The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tacrolimus. |
| Insulin Glulisine | The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tacrolimus. |
| Insulin Lispro | The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus. |
| Insulin Regular | The therapeutic efficacy of Insulin Regular can be decreased when used in combination with Tacrolimus. |
| Insulin, isophane | The therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Tacrolimus. |
| Irinotecan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Irinotecan. |
| Isoflurophate | The metabolism of Tacrolimus can be decreased when combined with Isoflurophate. |
| Isradipine | The serum concentration of Tacrolimus can be increased when it is combined with Isradipine. |
| Itraconazole | The metabolism of Tacrolimus can be decreased when combined with Itraconazole. |
| Ivacaftor | The serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The metabolism of Tacrolimus can be decreased when combined with Ketoconazole. |
| Ketoprofen | Ketoprofen may increase the nephrotoxic activities of Tacrolimus. |
| Ketorolac | Ketorolac may increase the nephrotoxic activities of Tacrolimus. |
| L-Phenylalanine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with L-Phenylalanine. |
| Lansoprazole | The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Tacrolimus. |
| Leflunomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide. |
| Leuprolide | Tacrolimus may increase the QTc-prolonging activities of Leuprolide. |
| Levofloxacin | Levofloxacin may increase the QTc-prolonging activities of Tacrolimus. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Tacrolimus. |
| Lomustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lomustine. |
| Lopinavir | The metabolism of Tacrolimus can be decreased when combined with Lopinavir. |
| Luliconazole | The serum concentration of Tacrolimus can be increased when it is combined with Luliconazole. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mechlorethamine. |
| Mefenamic acid | Mefenamic acid may increase the nephrotoxic activities of Tacrolimus. |
| Meloxicam | Meloxicam may increase the nephrotoxic activities of Tacrolimus. |
| Melphalan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Melphalan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mercaptopurine. |
| Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Tacrolimus. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus. |
| Methotrexate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone. |
| Mifepristone | Mifepristone may increase the QTc-prolonging activities of Tacrolimus. |
| Mitomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitomycin. |
| Mitotane | The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitoxantrone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolic acid. |
| Nabumetone | Nabumetone may increase the nephrotoxic activities of Tacrolimus. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Tacrolimus. |
| Naproxen | Naproxen may increase the nephrotoxic activities of Tacrolimus. |
| Natalizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab. |
| Nefazodone | The metabolism of Tacrolimus can be decreased when combined with Nefazodone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nelarabine. |
| Nelfinavir | The metabolism of Tacrolimus can be decreased when combined with Nelfinavir. |
| Netupitant | The serum concentration of Tacrolimus can be increased when it is combined with Netupitant. |
| Nicardipine | The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine. |
| Nifedipine | The serum concentration of Tacrolimus can be increased when it is combined with Nifedipine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nilotinib. |
| Nimodipine | The serum concentration of Tacrolimus can be increased when it is combined with Nimodipine. |
| Nisoldipine | The serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab. |
| Omeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Omeprazole. |
| Osimertinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Osimertinib. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may increase the nephrotoxic activities of Tacrolimus. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel. |
| Palbociclib | The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib. |
| Panobinostat | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Panobinostat. |
| Pantoprazole | The serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pegaspargase. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed. |
| Pentostatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pentostatin. |
| Phenytoin | The serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tacrolimus. |
| Piroxicam | Piroxicam may increase the nephrotoxic activities of Tacrolimus. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide. |
| Posaconazole | The metabolism of Tacrolimus can be decreased when combined with Posaconazole. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pralatrexate. |
| Prednisolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Procarbazine. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Tacrolimus. |
| Rabeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole. |
| Ranolazine | The serum concentration of Tacrolimus can be increased when it is combined with Ranolazine. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus. |
| Repository corticotropin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Repository corticotropin. |
| Rifabutin | The serum concentration of Tacrolimus can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Tacrolimus can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Tacrolimus can be decreased when it is combined with Rifapentine. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Tacrolimus. |
| Rilonacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rilonacept. |
| Ritonavir | The metabolism of Tacrolimus can be decreased when combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rituximab. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Tacrolimus. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ruxolitinib. |
| Saquinavir | The metabolism of Tacrolimus can be decreased when combined with Saquinavir. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Tacrolimus. |
| Secukinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Secukinumab. |
| Sevelamer | The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer. |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Tacrolimus. |
| Siltuximab | The serum concentration of Tacrolimus can be decreased when it is combined with Siltuximab. |
| Simeprevir | The metabolism of Tacrolimus can be decreased when combined with Simeprevir. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus. |
| Sirolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus. |
| Sorafenib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib. |
| Spironolactone | Spironolactone may increase the hyperkalemic activities of Tacrolimus. |
| St. John's Wort | The serum concentration of Tacrolimus can be decreased when it is combined with St. John's Wort. |
| Stiripentol | The serum concentration of Tacrolimus can be increased when it is combined with Stiripentol. |
| Streptozocin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Streptozocin. |
| Sulfisoxazole | The serum concentration of Tacrolimus can be increased when it is combined with Sulfisoxazole. |
| Sulindac | Sulindac may increase the nephrotoxic activities of Tacrolimus. |
| Sunitinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sunitinib. |
| Telaprevir | The serum concentration of Tacrolimus can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Telithromycin. |
| Temozolomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus. |
| Teniposide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Teniposide. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Teriflunomide. |
| Tesmilifene | The serum concentration of Tacrolimus can be decreased when it is combined with Tesmilifene. |
| Thalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thalidomide. |
| Thiotepa | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thiotepa. |
| Tiaprofenic acid | Tiaprofenic acid may increase the nephrotoxic activities of Tacrolimus. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tioguanine. |
| Tipranavir | The metabolism of Tacrolimus can be decreased when combined with Tipranavir. |
| Tocilizumab | The serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab. |
| Tofacitinib | Tacrolimus may increase the immunosuppressive activities of Tofacitinib. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus. |
| Tolmetin | Tolmetin may increase the nephrotoxic activities of Tacrolimus. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Tacrolimus. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tositumomab. |
| Trabectedin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Trabectedin. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Tacrolimus. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone. |
| Triamterene | Triamterene may increase the hyperkalemic activities of Tacrolimus. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ustekinumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vedolizumab. |
| Verapamil | The metabolism of Tacrolimus can be decreased when combined with Verapamil. |
| Vilanterol | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vilanterol. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tacrolimus. |
| Vinblastine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vincristine. |
| Vindesine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vindesine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinorelbine. |
| Voriconazole | The metabolism of Tacrolimus can be decreased when combined with Voriconazole. |
| Drug | Interaction |
|---|---|
| Abatacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Abatacept. |
| Acetohexamide | The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus. |
| Adalimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab. |
| ado-trastuzumab emtansine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with ado-trastuzumab emtansine. |
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Tacrolimus. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alemtuzumab. |
| Alogliptin | The therapeutic efficacy of Alogliptin can be decreased when used in combination with Tacrolimus. |
| Altretamine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Altretamine. |
| Amiloride | Amiloride may increase the hyperkalemic activities of Tacrolimus. |
| Amlodipine | The serum concentration of Tacrolimus can be increased when it is combined with Amlodipine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Amsacrine. |
| Anakinra | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra. |
| Anti-thymocyte Globulin (Rabbit) | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anti-thymocyte Globulin (Rabbit). |
| Aprepitant | The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant. |
| Atazanavir | The metabolism of Tacrolimus can be decreased when combined with Atazanavir. |
| Azacitidine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azacitidine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Azathioprine. |
| Azithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin. |
| Basil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basil. |
| Basiliximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basiliximab. |
| Batimastat | The metabolism of Tacrolimus can be decreased when combined with Batimastat. |
| Belatacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belatacept. |
| Belimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Belimumab. |
| Betamethasone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Betamethasone. |
| Bexarotene | The serum concentration of Tacrolimus can be decreased when it is combined with Bexarotene. |
| Bleomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Bleomycin. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Blinatumomab. |
| Boceprevir | The serum concentration of Tacrolimus can be increased when it is combined with Boceprevir. |
| Bosentan | The serum concentration of Tacrolimus can be decreased when it is combined with Bosentan. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Brentuximab vedotin. |
| Budesonide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide. |
| Busulfan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Busulfan. |
| Cabazitaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel. |
| Canagliflozin | The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus. |
| Canakinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Canakinumab. |
| Capecitabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Capecitabine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carboplatin. |
| Carmustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Carmustine. |
| Caspofungin | The serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin. |
| Celecoxib | Celecoxib may increase the nephrotoxic activities of Tacrolimus. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Certolizumab pegol. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Chlorambucil. |
| Chloramphenicol | The serum concentration of Tacrolimus can be increased when it is combined with Chloramphenicol. |
| Chlorpropamide | The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tacrolimus. |
| Choline fenofibrate | Tacrolimus may increase the nephrotoxic activities of Choline fenofibrate. |
| Cinacalcet | The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet. |
| Cisplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cisplatin. |
| Citalopram | Tacrolimus may increase the QTc-prolonging activities of Citalopram. |
| Cladribine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cladribine. |
| Clarithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Clarithromycin. |
| Clofarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clofarabine. |
| Clotrimazole | The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole. |
| Clozapine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Clozapine. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Tacrolimus. |
| Conivaptan | The serum concentration of Tacrolimus can be increased when it is combined with Conivaptan. |
| Corticotropin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cortisone acetate. |
| Crizotinib | The serum concentration of Tacrolimus can be increased when it is combined with Crizotinib. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cyclophosphamide. |
| Cyclosporine | Tacrolimus may increase the nephrotoxic activities of Cyclosporine. |
| Cytarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Cytarabine. |
| Dabigatran etexilate | The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrolimus. |
| Dabrafenib | The serum concentration of Tacrolimus can be decreased when it is combined with Dabrafenib. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dactinomycin. |
| Danazol | The serum concentration of Tacrolimus can be increased when it is combined with Danazol. |
| Darunavir | The metabolism of Tacrolimus can be decreased when combined with Darunavir. |
| Dasatinib | The serum concentration of Tacrolimus can be increased when it is combined with Dasatinib. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Daunorubicin. |
| Deferasirox | The serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox. |
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus. |
| Dexamethasone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dexamethasone. |
| Diclofenac | Diclofenac may increase the nephrotoxic activities of Tacrolimus. |
| Diflunisal | Diflunisal may increase the nephrotoxic activities of Tacrolimus. |
| Diltiazem | The metabolism of Tacrolimus can be decreased when combined with Diltiazem. |
| Dinutuximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Dinutuximab. |
| Docetaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel. |
| Dofetilide | Tacrolimus may increase the QTc-prolonging activities of Dofetilide. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxorubicin. |
| Dronedarone | Tacrolimus may increase the QTc-prolonging activities of Dronedarone. |
| Eculizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Eculizumab. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Tacrolimus. |
| Efavirenz | The serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz. |
| Efonidipine | The serum concentration of Tacrolimus can be increased when it is combined with Efonidipine. |
| Enzalutamide | The serum concentration of Tacrolimus can be decreased when it is combined with Enzalutamide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Epirubicin. |
| Eplerenone | Eplerenone may increase the hyperkalemic activities of Tacrolimus. |
| Ertapenem | The serum concentration of Tacrolimus can be increased when it is combined with Ertapenem. |
| Erythromycin | The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin. |
| Esomeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Esomeprazole. |
| Estramustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Estramustine. |
| Etanercept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etanercept. |
| Ethanol | Ethanol can cause an increase in the absorption of Tacrolimus resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Etodolac | Etodolac may increase the nephrotoxic activities of Tacrolimus. |
| Etoposide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Etoposide. |
| Everolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Everolimus. |
| Felodipine | The serum concentration of Tacrolimus can be increased when it is combined with Felodipine. |
| Fenofibrate | Tacrolimus may increase the nephrotoxic activities of Fenofibrate. |
| Fenoprofen | Fenoprofen may increase the nephrotoxic activities of Tacrolimus. |
| Fingolimod | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fingolimod. |
| Floctafenine | Floctafenine may increase the nephrotoxic activities of Tacrolimus. |
| Floxuridine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Floxuridine. |
| Fluconazole | The metabolism of Tacrolimus can be decreased when combined with Fluconazole. |
| Fludarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludarabine. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluorouracil. |
| Flurbiprofen | Flurbiprofen may increase the nephrotoxic activities of Tacrolimus. |
| Fluticasone Propionate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Fluticasone Propionate. |
| Fosamprenavir | The metabolism of Tacrolimus can be decreased when combined with Fosamprenavir. |
| Fosaprepitant | The serum concentration of Tacrolimus can be increased when it is combined with Fosaprepitant. |
| Foscarnet | Foscarnet may increase the nephrotoxic activities of Tacrolimus. |
| Fosphenytoin | The serum concentration of Tacrolimus can be decreased when it is combined with Fosphenytoin. |
| Fusidic Acid | The serum concentration of Tacrolimus can be increased when it is combined with Fusidic Acid. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemcitabine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemtuzumab ozogamicin. |
| Glatiramer Acetate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Glatiramer Acetate. |
| Gliclazide | The therapeutic efficacy of Gliclazide can be decreased when used in combination with Tacrolimus. |
| Glimepiride | The therapeutic efficacy of Glimepiride can be decreased when used in combination with Tacrolimus. |
| Gliquidone | The therapeutic efficacy of Gliquidone can be decreased when used in combination with Tacrolimus. |
| Glyburide | The therapeutic efficacy of Glyburide can be decreased when used in combination with Tacrolimus. |
| golimumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with golimumab. |
| Goserelin | Tacrolimus may increase the QTc-prolonging activities of Goserelin. |
| Hydrocortisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydrocortisone. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Hydroxyurea. |
| Ibritumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibritumomab. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibrutinib. |
| Ibuprofen | Ibuprofen may increase the nephrotoxic activities of Tacrolimus. |
| Idarubicin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Idarubicin. |
| Idelalisib | The serum concentration of Tacrolimus can be increased when it is combined with Idelalisib. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ifosfamide. |
| Imatinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imatinib. |
| Imiquimod | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Imiquimod. |
| Indinavir | The metabolism of Tacrolimus can be decreased when combined with Indinavir. |
| Indomethacin | Indomethacin may increase the nephrotoxic activities of Tacrolimus. |
| Infliximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab. |
| Insulin Aspart | The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tacrolimus. |
| Insulin Detemir | The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tacrolimus. |
| Insulin Glargine | The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tacrolimus. |
| Insulin Glulisine | The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tacrolimus. |
| Insulin Lispro | The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus. |
| Insulin Regular | The therapeutic efficacy of Insulin Regular can be decreased when used in combination with Tacrolimus. |
| Insulin, isophane | The therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Tacrolimus. |
| Irinotecan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Irinotecan. |
| Isoflurophate | The metabolism of Tacrolimus can be decreased when combined with Isoflurophate. |
| Isradipine | The serum concentration of Tacrolimus can be increased when it is combined with Isradipine. |
| Itraconazole | The metabolism of Tacrolimus can be decreased when combined with Itraconazole. |
| Ivacaftor | The serum concentration of Tacrolimus can be increased when it is combined with Ivacaftor. |
| Ketoconazole | The metabolism of Tacrolimus can be decreased when combined with Ketoconazole. |
| Ketoprofen | Ketoprofen may increase the nephrotoxic activities of Tacrolimus. |
| Ketorolac | Ketorolac may increase the nephrotoxic activities of Tacrolimus. |
| L-Phenylalanine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with L-Phenylalanine. |
| Lansoprazole | The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Tacrolimus. |
| Leflunomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Leflunomide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide. |
| Leuprolide | Tacrolimus may increase the QTc-prolonging activities of Leuprolide. |
| Levofloxacin | Levofloxacin may increase the QTc-prolonging activities of Tacrolimus. |
| Linagliptin | The therapeutic efficacy of Linagliptin can be decreased when used in combination with Tacrolimus. |
| Lomustine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Lomustine. |
| Lopinavir | The metabolism of Tacrolimus can be decreased when combined with Lopinavir. |
| Luliconazole | The serum concentration of Tacrolimus can be increased when it is combined with Luliconazole. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mechlorethamine. |
| Mefenamic acid | Mefenamic acid may increase the nephrotoxic activities of Tacrolimus. |
| Meloxicam | Meloxicam may increase the nephrotoxic activities of Tacrolimus. |
| Melphalan | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Melphalan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mercaptopurine. |
| Metamizole | The risk or severity of adverse effects can be increased when Metamizole is combined with Tacrolimus. |
| Metformin | The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus. |
| Methotrexate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methotrexate. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Methylprednisolone. |
| Mifepristone | Mifepristone may increase the QTc-prolonging activities of Tacrolimus. |
| Mitomycin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitomycin. |
| Mitotane | The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mitoxantrone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolate mofetil. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolic acid. |
| Nabumetone | Nabumetone may increase the nephrotoxic activities of Tacrolimus. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Tacrolimus. |
| Naproxen | Naproxen may increase the nephrotoxic activities of Tacrolimus. |
| Natalizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab. |
| Nefazodone | The metabolism of Tacrolimus can be decreased when combined with Nefazodone. |
| Nelarabine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nelarabine. |
| Nelfinavir | The metabolism of Tacrolimus can be decreased when combined with Nelfinavir. |
| Netupitant | The serum concentration of Tacrolimus can be increased when it is combined with Netupitant. |
| Nicardipine | The serum concentration of Tacrolimus can be increased when it is combined with Nicardipine. |
| Nifedipine | The serum concentration of Tacrolimus can be increased when it is combined with Nifedipine. |
| Nilotinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Nilotinib. |
| Nimodipine | The serum concentration of Tacrolimus can be increased when it is combined with Nimodipine. |
| Nisoldipine | The serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab. |
| Omeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Omeprazole. |
| Osimertinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Osimertinib. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Oxaliplatin. |
| Oxaprozin | Oxaprozin may increase the nephrotoxic activities of Tacrolimus. |
| Paclitaxel | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Paclitaxel. |
| Palbociclib | The serum concentration of Tacrolimus can be increased when it is combined with Palbociclib. |
| Panobinostat | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Panobinostat. |
| Pantoprazole | The serum concentration of Tacrolimus can be increased when it is combined with Pantoprazole. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pegaspargase. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pemetrexed. |
| Pentostatin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pentostatin. |
| Phenytoin | The serum concentration of Tacrolimus can be decreased when it is combined with Phenytoin. |
| Pimecrolimus | The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tacrolimus. |
| Piroxicam | Piroxicam may increase the nephrotoxic activities of Tacrolimus. |
| Pomalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide. |
| Posaconazole | The metabolism of Tacrolimus can be decreased when combined with Posaconazole. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pralatrexate. |
| Prednisolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone. |
| Prednisone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Procarbazine. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Tacrolimus. |
| Rabeprazole | The serum concentration of Tacrolimus can be increased when it is combined with Rabeprazole. |
| Ranolazine | The serum concentration of Tacrolimus can be increased when it is combined with Ranolazine. |
| Repaglinide | The therapeutic efficacy of Repaglinide can be decreased when used in combination with Tacrolimus. |
| Repository corticotropin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Repository corticotropin. |
| Rifabutin | The serum concentration of Tacrolimus can be decreased when it is combined with Rifabutin. |
| Rifampicin | The serum concentration of Tacrolimus can be decreased when it is combined with Rifampicin. |
| Rifapentine | The serum concentration of Tacrolimus can be decreased when it is combined with Rifapentine. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Tacrolimus. |
| Rilonacept | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rilonacept. |
| Ritonavir | The metabolism of Tacrolimus can be decreased when combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rituximab. |
| Roflumilast | Roflumilast may increase the immunosuppressive activities of Tacrolimus. |
| Ruxolitinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ruxolitinib. |
| Saquinavir | The metabolism of Tacrolimus can be decreased when combined with Saquinavir. |
| Saxagliptin | The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Tacrolimus. |
| Secukinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Secukinumab. |
| Sevelamer | The serum concentration of Tacrolimus can be decreased when it is combined with Sevelamer. |
| Silodosin | The serum concentration of Silodosin can be increased when it is combined with Tacrolimus. |
| Siltuximab | The serum concentration of Tacrolimus can be decreased when it is combined with Siltuximab. |
| Simeprevir | The metabolism of Tacrolimus can be decreased when combined with Simeprevir. |
| Sipuleucel-T | The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus. |
| Sirolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sirolimus. |
| Sorafenib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sorafenib. |
| Spironolactone | Spironolactone may increase the hyperkalemic activities of Tacrolimus. |
| St. John's Wort | The serum concentration of Tacrolimus can be decreased when it is combined with St. John's Wort. |
| Stiripentol | The serum concentration of Tacrolimus can be increased when it is combined with Stiripentol. |
| Streptozocin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Streptozocin. |
| Sulfisoxazole | The serum concentration of Tacrolimus can be increased when it is combined with Sulfisoxazole. |
| Sulindac | Sulindac may increase the nephrotoxic activities of Tacrolimus. |
| Sunitinib | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Sunitinib. |
| Telaprevir | The serum concentration of Tacrolimus can be increased when it is combined with Telaprevir. |
| Telithromycin | The serum concentration of Tacrolimus can be increased when it is combined with Telithromycin. |
| Temozolomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temozolomide. |
| Temsirolimus | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Temsirolimus. |
| Teniposide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Teniposide. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Teriflunomide. |
| Tesmilifene | The serum concentration of Tacrolimus can be decreased when it is combined with Tesmilifene. |
| Thalidomide | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thalidomide. |
| Thiotepa | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Thiotepa. |
| Tiaprofenic acid | Tiaprofenic acid may increase the nephrotoxic activities of Tacrolimus. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tioguanine. |
| Tipranavir | The metabolism of Tacrolimus can be decreased when combined with Tipranavir. |
| Tocilizumab | The serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab. |
| Tofacitinib | Tacrolimus may increase the immunosuppressive activities of Tofacitinib. |
| Tolbutamide | The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tacrolimus. |
| Tolmetin | Tolmetin may increase the nephrotoxic activities of Tacrolimus. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Tacrolimus. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tositumomab. |
| Trabectedin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Trabectedin. |
| Trastuzumab | Trastuzumab may increase the neutropenic activities of Tacrolimus. |
| Tretinoin | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tretinoin. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone. |
| Triamterene | Triamterene may increase the hyperkalemic activities of Tacrolimus. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ustekinumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vedolizumab. |
| Verapamil | The metabolism of Tacrolimus can be decreased when combined with Verapamil. |
| Vilanterol | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vilanterol. |
| Vildagliptin | The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Tacrolimus. |
| Vinblastine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinblastine. |
| Vincristine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vincristine. |
| Vindesine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vindesine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinorelbine. |
| Voriconazole | The metabolism of Tacrolimus can be decreased when combined with Voriconazole. |
Food Interactions:
- Food, especially food with a high-fat content, decreases the rate and extent of absorption.
- The time of the meal affects tacrolimus bioavailability. Take tacrolimus capsules consistently everyday either with or without food.
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Alpha amino acid esters
- Azacyclic compounds
- Carboxylic acid esters
- Cyclic alcohols and derivatives
- Cyclic ketones
- Cyclohexanols
- Dialkyl ethers
- Hemiacetals
- Hydrocarbon derivatives
- Lactams
- Lactones
- Macrolides and analogues
- Monocarboxylic acids and derivatives
- Oxacyclic compounds
- Oxanes
- Piperidines
- Tertiary amines
- Tertiary carboxylic acid amides
substituent:
- Alcohol
- Aliphatic heteropolycyclic compound
- Alpha-amino acid ester
- Amine
- Azacycle
- Carbonyl group
- Carboxamide group
- Carboxylic acid derivative
- Carboxylic acid ester
- Cyclic alcohol
- Cyclic ketone
- Cyclohexanol
- Dialkyl ether
- Ether
- Hemiacetal
- Hydrocarbon derivative
- Ketone
- Lactam
- Lactone
- Macrolide
- Macrolide lactam
- Monocarboxylic acid or derivatives
- Organoheterocyclic compound
- Organonitrogen compound
- Organooxygen compound
- Oxacycle
- Oxane
- Piperidine
- Secondary alcohol
- Tertiary amine
- Tertiary carboxylic acid amide
References
Synthesis Reference: Pan Sup Chang, Hoon Cho, "Water soluble polymer-tacrolimus conjugated compounds and process for preparing the same." U.S. Patent US5922729, issued April, 1997.
General Reference: # Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2445721 # Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15896681 # Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1715244 # Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K: Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet. 2006 Apr;21(2):122-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16702731 # Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 2):S186-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16021174 # FDA label
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, Imanaka H: FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2445721 # Pritchard DI: Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005 May 15;10(10):688-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15896681 # Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1715244 # Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K: Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet. 2006 Apr;21(2):122-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16702731 # Hanifin JM, Paller AS, Eichenfield L, Clark RA, Korman N, Weinstein G, Caro I, Jaracz E, Rico MJ: Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 2):S186-94. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16021174 # FDA label
External Links:
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic2/tacrolimus.htm |
| Drugs.com | http://www.drugs.com/cdi/tacrolimus.html |
| Resource | Link |
|---|---|
| RxList | http://www.rxlist.com/cgi/generic2/tacrolimus.htm |
| Drugs.com | http://www.drugs.com/cdi/tacrolimus.html |
ATC Codes:
- Array
- Array
AHFS Codes:
- 84:92.00
- 92:00.00
MSDS: Download